Stem Cell Research & Therapy, 2022 · DOI: https://doi.org/10.1186/s13287-022-03103-8 · Published: August 3, 2022
This study examines the potential of umbilical cord mesenchymal stem cells (UCMSCs) for treating spinal cord injuries (SCI). It seeks to identify the best way to transplant these cells to maximize their therapeutic effect. The researchers analyzed data from 40 animal studies, comparing different doses, routes of administration (local vs. intravenous), and timing of UCMSC transplantation in SCI animal models. The goal is to provide guidance for future animal research and clinical trials, ultimately improving the functional recovery of patients with spinal cord injuries.
Findings suggest that clinical trials investigating UCMSC therapy for SCI should prioritize high-dose, local delivery during the subacute phase of injury.
Future animal studies should focus on addressing the limitations identified, such as implementing rigorous blinding procedures and extending follow-up periods.
Researchers should consider the differences between animal models and human SCI when translating findings, particularly regarding the chronic nature of most human injuries.